All In Biotech

Drug Trial Radar · NCT00262821

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis

Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

402

Actual

Start

Feb 2006

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Sponsor type
NIH
Collaborators
NCIC Clinical Trials Group; Gynecologic Oncology Group
First posted
Dec 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Cisplatin and tirapazamine may make tumor cells more sensitive to radiation therapy. It is not yet known whether giving cisplatin together with radiation therapy is more effective with or without tirapazamine in treating cervical cancer.

Conditions

  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Cell Carcinoma
  • Cervical Squamous Cell Carcinoma
  • Stage IB Cervical Cancer
  • Stage IIA Cervical Cancer
  • Stage IIB Cervical Cancer
  • Stage III Cervical Cancer
  • Stage IVA Cervical Cancer

Interventions

  • cisplatinDrug

    Given IV

  • tirapazamineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival - Percentage of Patients Alive and Progression FreeTime frame: From study entry until first disease progression, death or date of last contact, up to 6 years

Locations

282 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Banner Good Samaritan Medical Center

    Phoenix, Arizona

  • Western Regional CCOP

    Phoenix, Arizona

  • Highlands Oncology Group PA - Fayetteville

    Fayetteville, Arkansas

  • Washington Regional Medical Center - Fayetteville

    Fayetteville, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • City of Hope Medical Center

    Duarte, California

  • Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Bay Area Tumor Institute CCOP

    Oakland, California

  • University of California Medical Center At Irvine-Orange Campus

    Orange, California

  • Pomona Valley Hospital Medical Center

    Pomona, California

  • Stanford University Hospitals and Clinics

    Stanford, California

  • Olive View-University of California Los Angeles Medical Center

    Sylmar, California

  • Colorado Gynecologic Oncology Group

    Aurora, Colorado

  • Memorial Hospital Colorado Springs

    Colorado Springs, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Yale University

    New Haven, Connecticut

  • Beebe Medical Center

    Lewes, Delaware

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Florida Gynecologic Oncology

    Fort Myers, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • UF Cancer Center at Orlando Health

    Orlando, Florida

  • Piedmont Hospital

    Atlanta, Georgia

  • Northside Hospital

    Atlanta, Georgia

  • Saint Joseph's Hospital of Atlanta

    Atlanta, Georgia

  • Georgia Regents University

    Augusta, Georgia

  • John B Amos Cancer Center

    Columbus, Georgia

  • Dekalb Medical Center

    Decatur, Georgia

  • Wellstar Kennestone Hospital

    Marietta, Georgia

  • Memorial Health University Medical Center

    Savannah, Georgia

  • Pali Momi Medical Center

    ‘Aiea, Hawaii

  • Hawaii Minority Based CCOP

    Honolulu, Hawaii

  • Queen's Medical Center

    Honolulu, Hawaii

Showing 40 of 282 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.